Ledipasvir & Sofosbuvir Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Dual-Active FDC Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles with specialized desiccants to ensure the absolute chemical survival of the complex antiviral APIs.
Active Ingredient Strength Primary Clinical Function Ledipasvir USP/Ph.Eur. 90 mg The NS5A Anchor: Potent inhibitor of viral assembly and secretion; highly effective against specific HCV genotypes. Sofosbuvir USP/Ph.Eur. 400 mg The NS5B Backbone: The globally recognized foundational DAA that forces viral RNA chain termination across multiple genotypes. Excipients Copovidone / Lactose Monohydrate / Microcrystalline Cellulose / Croscarmellose Sodium / Magnesium Stearate / Premium Opadry Film Binder / Diluent / Superdisintegrant / Lubricant / Film-Coating (Engineered specifically to solve the massive solubility differences between the highly soluble Sofosbuvir and the poorly soluble Ledipasvir, guaranteeing synchronized gastric release and peak systemic absorption) *Pack Sizes: Bottles of 28 (Optimized specifically for the strict 4-week dispensing intervals required for 8, 12, or 24-week curative regimens).
Sofosbuvir & Ledipasvir Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant heavy-gauge HDPE bottles containing exactly 28 tablets to perfectly align with strict clinical dispensing cycles.
Active Ingredient Strength Primary Clinical Function Sofosbuvir INN/Ph.Eur. 400 mg NS5B RNA polymerase inhibition to terminate viral RNA chain synthesis. Ledipasvir INN/Ph.Eur. 90 mg NS5A protein inhibition to halt viral replication and physical virion assembly. Excipients Copovidone / Lactose Monohydrate / Microcrystalline Cellulose / Croscarmellose Sodium / Magnesium Stearate Binder / Diluent / Superdisintegrant (Engineered for strict synchronized gastric dissolution) Sofosbuvir & Velpatasvir Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant heavy-gauge HDPE bottles containing exactly 28 tablets to perfectly align with strict 12-week clinical dispensing cycles.
Active Ingredient Strength Primary Clinical Function Sofosbuvir INN/Ph.Eur. 400 mg NS5B RNA polymerase inhibition to terminate viral RNA chain synthesis. Velpatasvir INN/Ph.Eur. 100 mg NS5A protein inhibition to halt viral replication and physical virion assembly. Excipients Copovidone / Microcrystalline Cellulose / Croscarmellose Sodium / Magnesium Stearate Binder / Diluent / Superdisintegrant (Engineered for strict synchronized gastric dissolution) Sofosbuvir Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant heavy-gauge HDPE bottles or ultra-dense Alu-Alu blister strips to ensure the absolute chemical stability of the nucleotide analog.
Active Ingredient Strength Primary Clinical Function Sofosbuvir INN/Ph.Eur. 400 mg Global Standard: Base NS5B polymerase inhibition for daily combination HCV therapy. Excipients Mannitol / Microcrystalline Cellulose / Croscarmellose Sodium / Colloidal Silicon Dioxide / Magnesium Stearate Diluent / Superdisintegrant / Glidant (Engineered for immediate gastric dissolution and high bioavailability)
Showing all 4 results
